Why Alignment Healthcare (ALHC) Is Up 5.5% After Returning to Profit and Raising Revenue Guidance

Simply Wall St.
Aug 08
  • Alignment Healthcare reported its second quarter 2025 results in the past week, posting US$1.02 billion in revenue and turning its prior-year net loss into a net profit of US$15.67 million, alongside raising its full-year revenue guidance to between US$3.89 billion and US$3.91 billion.
  • This turnaround from loss to profit and the raised revenue outlook highlight both operational improvement and increased management confidence in future growth.
  • We'll examine how Alignment Healthcare's improved profitability and upgraded revenue guidance may impact its investment narrative, especially around margin expansion.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Advertisement

Alignment Healthcare Investment Narrative Recap

To be a shareholder in Alignment Healthcare, you need to believe in the company’s ability to grow its membership base and execute operational improvements that lift profitability and margins in a competitive Medicare Advantage space. The recent turnaround from a net loss to a net profit, coupled with upgraded revenue guidance, suggests operational gains, though the sustainability of membership growth remains the most important short-term catalyst. The main risk is that a slowdown in membership expansion could quickly affect revenue momentum, so the news supports, but does not fundamentally alter, this narrative.

The most relevant recent announcement is the raised 2025 revenue guidance to a range of US$3,885 million to US$3,910 million. This ties directly to ongoing investor focus on top-line growth and margin performance, reinforcing confidence in improving operational leverage, but it does not eliminate the underlying challenge of maintaining robust membership growth as the primary driver of revenue.

On the other hand, investors should be aware that if membership growth falters…

Read the full narrative on Alignment Healthcare (it's free!)

Alignment Healthcare's narrative projects $6.2 billion revenue and $82.9 million earnings by 2028. This requires 27.1% yearly revenue growth and a $173.5 million increase in earnings from the current -$90.6 million.

Uncover how Alignment Healthcare's forecasts yield a $18.40 fair value, a 34% upside to its current price.

Exploring Other Perspectives

ALHC Earnings & Revenue Growth as at Aug 2025

Simply Wall St Community members estimated fair values for Alignment Healthcare between US$14.22 and US$18.40, with just 2 perspectives included. While the latest raised revenue guidance highlights margin improvement potential, outcomes may still depend on sustained membership gains, so you can explore more diverse community viewpoints to see how opinions differ.

Explore 2 other fair value estimates on Alignment Healthcare - why the stock might be worth as much as 34% more than the current price!

Build Your Own Alignment Healthcare Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

  • A great starting point for your Alignment Healthcare research is our analysis highlighting 5 key rewards that could impact your investment decision.
  • Our free Alignment Healthcare research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alignment Healthcare's overall financial health at a glance.

Looking For Alternative Opportunities?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

  • The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 20 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
  • Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
  • Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10